Altered pigment epithelium-derived factor and vascular endothelial growth factor levels in lymphangioma pathogenesis and clinical recurrence

Archives of Otolaryngology - Head and Neck Surgery

Volumn 131, Issue 11, 2005, Pages 990-995

  Sidle, Douglas M ^a   Maddalozzo, John ^a,b,c   Meier, Jason D ^a   Cornwell, Mona ^a   Stellmach, Veronica ^a   Crawford, Susan E ^a  

^a Department of Otolaryngology Head and Neck Surgery ^*  (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c CHILDREN'S MEMORIAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; PIGMENT EPITHELIUM DERIVED FACTOR; VASCULOTROPIN;

ANGIOGENESIS; ARTICLE; CANCER PATIENT; CANCER RECURRENCE; CHILD; CLINICAL ARTICLE; CORRELATION ANALYSIS; EXCISION; FEMALE; FIBROSIS; FOLLOW UP; HEAD AND NECK TUMOR; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFANT; INFLAMMATION; LYMPHANGIOMA; MALE; MEDICAL INFORMATION; MICROANGIOPATHY; ONSET AGE; PATHOGENESIS; PEDIATRIC HOSPITAL; PROTEIN EXPRESSION; RECURRENT DISEASE; RETROSPECTIVE STUDY; STAINING; STROMA; TUMOR LOCALIZATION;

CHILD; CHILD WELFARE; CHILD, PRESCHOOL; EYE PROTEINS; FEMALE; FOLLOW-UP STUDIES; HEAD AND NECK NEOPLASMS; HUMANS; ILLINOIS; IMMUNOHISTOCHEMISTRY; INFANT; INFANT WELFARE; LYMPHANGIOMA; MALE; NEOPLASM RECURRENCE, LOCAL; NERVE GROWTH FACTORS; PROTEASE INHIBITORS; RETROSPECTIVE STUDIES; SERPINS; STATISTICS; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 28144453516     PISSN: 08864470     EISSN: 08864470     Source Type: Journal    
DOI: 10.1001/archotol.131.11.990     Document Type: Article

References (36)

1. Redenbacher E. De Ranula Sublingual, Speciali, Cum Casa Congenita. Munich, Germany: Monachii Lindauer; 1828.
2. Landing BH, Farber S. Tumors of the cardiovascular system. In: Landing BH, Farber S, eds. Atlas of Tumor Pathology. Washington, DC: Armed Forces Institute of Pathology; 1956:124-138.
3. Bill AH Jr, Sumner DS. A unified concept of lymphangioma and cystic hygroma. Surg Gynecol Obstet. 1965;120:79-86.
4. Williams HB. Embryology and classification of lymphatic abnormalities. In: Williams HB, ed. Symposium on Vascular Malformations and Melanotic Lesions. St Louis, Mo: Mosby; 1983:175-185.
5. Smith RJ, Burke DK, Sato Y, Poust RI, Kimura K, Bauman NM. OK-432 therapy for lymphangiomas. Arch Otolaryngol Head Neck Surg. 1996;122:1195-1199.
6. Batsakis JG. Tumors of the Head and Neck: Clinical and Pathological Considerations. 2nd ed. Baltimore, Md: Williams & Wilkins; 1979:301-304.
7. Emery PJ, Bailey CM, Evans JN. Cystic hygroma of the head and neck: a review of 37 cases. J Laryngol Otol. 1984;98:613-619.
8. Reinhardt MA, Nelson SC, Sencer SF, Bostrom BC, Kurachek SC, Nesbit ME. Treatment of childhood lymphangiomas with interferon-alpha. J Pediatr Hematol Oncol. 1997;19:232-236.
9. Fageeh N, Manoukian J, Tewfik T, Schloss M, Williams HB, Gaskin D. Mangagement of head and neck lymphatic malformations in children. J Otolaryngol. 1997;26:253-258.
10. Enzinger FM, Weiss SW. Tumors of lymph vessels. In: Enzinger FM, Weiss SW, eds. Soft Tissue Tumors. St Louis, Mo: Mosby-Year Book; 1995:679-688.
11. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1995;1:27-31.
12. Folkman J. New perspectives in clinical oncology from angiogenesis research. Eur J Cancer. 1996;32A:2534-2539.
13. Salven P, Heikkila P, Anttonen A, Kajanti M, Joensuu H. Vascular endothelial growth factor in squamous cell head and neck carcinoma: expression and prognostic significance. Mod Pathol. 1997;10:1128-1133.
14. Jia YT, Li ZX, He YT, Liang W, Yang HC, Ma HJ. Expression of vascular endothelial growth factor-C and the relationship between lymphangiogenesis and lymphatic metastasis in colorectal cancer. World J Gastroenterol. 2004;10:3261-3263.
15. Nishida N, Yano H, Komai K, Nishida T, Kamura T, Kojiro M. Vascular endothelial growth factor C and vascular endothelial growth factor receptor 2 are related closely to the prognosis of patients with ovarian carcinoma. Cancer. 2004;101:1364-1374.
16. Zeng Y, Opeskin K, Baldwin ME, et al. Expression of vascular endothelial growth factor receptor-3 by lymphatic endothelial cells is associated with lymph node metastasis in prostate cancer. Clin Cancer Res. 2004;10:5137-5144.
17. Tanigaki Y, Nagashima Y, Kitamura Y, Matsuda H, Mikami Y, Tsukuda M. The expression of vascular endothelial growth factor-A and -C, and receptor 1 and 3: correlation with lymph node metastasis and prognosis in tongue squamous cell carcinoma. Int J Mol Med. 2004;14:389-395.
18. Ogawa E, Takenaka K, Yanagihara K, et al. Clinical significance of VEGF-C status in tumour cells and stromal macrophages in non-small cell lung cancer patients. Br J Cancer. 2004;91:498-503.
19. Rowe RW, Tomoda M, Strebel FR, Jenkins GN, Stephens LC, Bull JM. The natural progression of microvasculature in primary tumor and lymph node metastases in a breast cancer model: relationship between microvessel density, vascular endothelial growth factor expression, and metastatic invasion. Cancer Biol Ther. 2004;3:408-414.
20. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev. 2004;25:581-611.
21. Fenton BM, Paoni SF, Ding I. Pathophysiological effects of vascular endothelial growth factor receptor-2 blocking antibody plus fractionated radiotherapy on murine mammary tumors. Cancer Res. 2004;64:5712-5719.
22. Penland SK, Goldberg RM. Combining anti-VEGF approaches with oxaliplatin in advanced colorectal cancer. Clin Colorectal Cancer. 2004;4(suppl 2):S74-S80.
23. Dawson DW, Volpert OV, Gillis P, et al. Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science. 1999;285:245-248.
24. Uehara H, Miyamoto M, Kato K, et al. Expression of pigment epithelium-derived factor decreases liver metastasis and correlates with favorable prognosis for patients with ductal pancreatic adenocarcinoma. Cancer Res. 2004;64:3533-3537.
25. Garcia M, Fernandez-Garcia NI, Rivas V, et al. Inhibition of xenografted human melanoma growth and prevention of metastasis development by dual antiangiogenic/ antitumor activities of pigment epithelium-derived factor. Cancer Res. 2004;64:5632-5642.
26. Abramson LP, Stellmach V, Doll JA, Cornwell M, Arensman RM, Crawford SE. Wilms' tumor growth is suppressed by antiangiogenic pigment epitheliumderived factor in a xenograft model. J Pediatr Surg. 2003;38:336-342.
27. Miyagishi D, Ohno-Matsui K, Amagasa T, Morita I. Regulation of the expression of pigment epithelium-derived factor, an anti-angiogenic factor in human oral squamous cell carcinoma cell lines. Cancer Lett. 2003;196:77-85.
28. Alberdi E, Aymerich MS, Becerra SP. Binding of pigment epithelium-derived factor (PEDF) to retinoblastoma cells and cerebellar granule neurons: evidence for a PEDF receptor. J Biol Chem. 1999;274:31605-31612.
29. Maddalozzo J, Hughes CA, Huang L, Mu Y, Ludemann J, Crawford S. High angiogenic activity in cells isolated from cystic hygroma: role of bFGF. Arch Otolaryngol Head Neck Surg. 1999;125:45-48.
30. Huang HY, Ho CC, Huang PH, Hsu SM. Co-expression of VEGF-C and its receptors, VEGFR-2 and VEGFR-3, in endothelial cells of lymphangioma: implication of autocrine or paracrine regulation of lymphangioma. Lab Invest. 2001;81:1729-1734.
31. Cohen SR, Thompson JW. Lymphangiomas of the larynx in infants and children: a survey of pediatric lymphangioma. Ann Otol Rhinol Laryngol Suppl. 1986;127:1-20.
32. Orvidas LJ, Kasperbauer JL. Pediatric lymphangiomas of the head and neck. Ann Otol Rhinol Laryngol. 2000;109:411-421.
33. Kukk E, Lymboussaki A, Taira S, et al. VEGF-C receptor binding and pattern of expression with VEGFR-3 suggests a role in lymphatic vascular development. Development. 1996;122:3829-3837.
34. Partanen TA, Alitalo K, Miettinen M. Lack of lymphatic vascular specificity of vascular endothelial growth factor receptor 3 in 185 vascular tumors. Cancer. 1999;86:2406-2412.
35. Cursiefen C, Schlotzer-Schrehardt U, Breiteneder-Geleff S, Holbach LM. Orbital lymphangioma with positive immunohistochemistry of lymphatic endothelial markers (vascular endothelial growth factor receptor 3 and podoplanin). Graefes Arch Clin Exp Ophthalmol. 2001;239:628-632.
36. Ricciardelli EJ, Richardson MA. Cervicofacial cystic hygroma. Patterns of recurrence and management of the difficult case. Arch Otolaryngol Head Neck Surg. 1991;117:546-553.